Table of ContentsView AllTable of ContentsMain Similarities and DifferencesWhat Is Adzenys?What Is Adderall?Safety PrecautionsSummary
Table of ContentsView All
View All
Table of Contents
Main Similarities and Differences
What Is Adzenys?
What Is Adderall?
Safety Precautions
Summary
Despite their similar purposes, Adzenys and Adderall differ in their formulations, how they’re administered, and how they are released in the body. Understanding these differences and similarities can help make informed decisions about ADHD treatment options that meet one’s individual needs.
Getty Images |Bloomberg/ Contributor
Adzenys is taken to treat ADHD in both children and adults.Its main ingredient is the stimulant amphetamine. By boosting levels of neurotransmitters like dopamine and norepinephrine, Adzenys helps improve focus, attention, and behavior in individuals with ADHD.
Adzenys offers several benefits for individuals with ADHD, including flexible dosing options. One key advantage is its extended-release formulation, which provides a consistent therapeutic effect throughout the day, reducing the need for multiple doses.The orally disintegrating tablet (ODT) form is also convenient for those who have difficulty swallowing pills because it dissolves easily on the tongue without water.
Adzenys has the same clinical efficacy as other mixed amphetamine extended-release formulations at equivalent doses. It also shares similar safety and tolerability characteristics.
Uses
Adzenys is primarily taken to treat ADHD in both children and adults. The U.S. Food and Drug Administration (FDA) has approved it for this specific purpose. It also helps to manage symptoms like inattention, hyperactivity, and impulsivity.
Side Effects
Adzenys can cause side effects that vary from person to person. Common side effects include:
Some may also experience headaches, nervousness, or irritability.
Most side effects are mild and manageable. However, it’s important to be aware of more serious risks, such as heart problems or mental health changes like mood swings or anxiety.
If you experience any concerning symptoms, talk to your healthcare provider. They can help adjust your dosage or explore other treatment options.
Adderall is highly effective at improving ADHD symptoms.Unlike Adzenys, it is available in both immediate-release and extended-release forms,which offers flexibility in managing symptoms throughout the day.
Adderall can cause side effects that vary in severity. Common side effects include:
In rare cases, Adderall may lead to more serious effects, such as heart-related issues, mood changes, or increased anxiety.
Monitor yourself for any unusual symptoms and discuss them with your healthcare provider.
Adzenys and Adderall are both controlled substances, which means they have a high potential for abuse that can lead to dependencies.In light of this, healthcare providers more strictly regulate them to ensure they are taken safely and appropriately.
Certain groups may be at a higher risk of experiencing side effects when taking Adderallor Adzenysincluding those with:
Drug Interactions
Adzenysand Adderallhave the potential to interact with:
Limit caffeine and alcohol intake while taking either medication because these substances may worsen adverse effects.
Special Considerations
Patients taking Adderall XR may be switched to Adzenys XR at an equivalent dose taken once daily. Adzenys 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, and 18.8 mg tablets are equivalent to 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg of Adderall XR, respectively.
Adderall dose adjustment is necessary in those with reduced kidney function.There are risks associated with the use of Adderalland Adzenysduring pregnancy. You should discuss them with your healthcare provider.
Adzenys and Adderall are both stimulant medications taken to manage ADHD. They treat similar conditions but have distinct differences in their formulations.
The ODT formulation of Adzenys allows the medication to dissolve on the tongue. This provides a steady drug release of the drug throughout the day, easier administration, and consistent symptom management. Adderall’s immediate-release form provides quicker onset relief, while its extended-release version offers prolonged symptom control.
Both medications require careful monitoring for potential side effects and interactions. Consider whether a long-acting or immediate-release formulation is more appropriate when choosing a medication.
6 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Steingard R, Taskiran S, Connor DF, et al.New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol. 2019;(5):324-339. doi:10.1089/cap.2019.0043.Swanson JM.Long-acting stimulants: development and dosing. Can Child Adolesc Psychiatr Rev. 2005 Aug;14(Supplement 1):4-9.Prescribers' Drug Reference.Adzenys XR.Prescribers' Digital Reference.Adderall XR.Cortese S, Adamo N, Del Giovane C, et al.Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.The Lancet Psychiatry.2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4Gabay M.Federal controlled substances act: controlled substances prescriptions.Hosp Pharm. 2013;48(8):644-5. doi:10.1310/hpj4808-644.
6 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Steingard R, Taskiran S, Connor DF, et al.New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol. 2019;(5):324-339. doi:10.1089/cap.2019.0043.Swanson JM.Long-acting stimulants: development and dosing. Can Child Adolesc Psychiatr Rev. 2005 Aug;14(Supplement 1):4-9.Prescribers' Drug Reference.Adzenys XR.Prescribers' Digital Reference.Adderall XR.Cortese S, Adamo N, Del Giovane C, et al.Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.The Lancet Psychiatry.2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4Gabay M.Federal controlled substances act: controlled substances prescriptions.Hosp Pharm. 2013;48(8):644-5. doi:10.1310/hpj4808-644.
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Steingard R, Taskiran S, Connor DF, et al.New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol. 2019;(5):324-339. doi:10.1089/cap.2019.0043.Swanson JM.Long-acting stimulants: development and dosing. Can Child Adolesc Psychiatr Rev. 2005 Aug;14(Supplement 1):4-9.Prescribers' Drug Reference.Adzenys XR.Prescribers' Digital Reference.Adderall XR.Cortese S, Adamo N, Del Giovane C, et al.Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.The Lancet Psychiatry.2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4Gabay M.Federal controlled substances act: controlled substances prescriptions.Hosp Pharm. 2013;48(8):644-5. doi:10.1310/hpj4808-644.
Steingard R, Taskiran S, Connor DF, et al.New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol. 2019;(5):324-339. doi:10.1089/cap.2019.0043.
Swanson JM.Long-acting stimulants: development and dosing. Can Child Adolesc Psychiatr Rev. 2005 Aug;14(Supplement 1):4-9.
Prescribers' Drug Reference.Adzenys XR.
Prescribers' Digital Reference.Adderall XR.
Cortese S, Adamo N, Del Giovane C, et al.Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.The Lancet Psychiatry.2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4
Gabay M.Federal controlled substances act: controlled substances prescriptions.Hosp Pharm. 2013;48(8):644-5. doi:10.1310/hpj4808-644.
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.Cookies SettingsAccept All Cookies
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies SettingsAccept All Cookies
